Glucose monitoring is a fact of everyday life for diabetic individuals. The accuracy of such monitoring can significantly affect the health and ultimately the quality of life of the person with diabetes. Generally, a diabetic patient measures blood glucose levels several times a day to monitor and control blood sugar levels. Failure to test blood glucose levels accurately and on a regular basis can result in serious diabetes-related complications, including cardiovascular disease, kidney disease, nerve damage and blindness. There are a number of electronic devices currently available which enable an individual to test the glucose level in a small sample of blood. One such glucose meter is the OneTouch® Profile™ glucose meter, a product which is manufactured by LifeScan.
In addition to glucose monitoring, diabetic individuals often have to maintain tight control over their lifestyle, so that they are not adversely affected by, for example, irregular food consumption or exercise. In addition, a physician dealing with a particular diabetic individual may require detailed information on the lifestyle of the individual to provide effective treatment or modification of treatment for controlling diabetes. Currently, one of the ways of monitoring the lifestyle of an individual with diabetes has been for the individual to keep a paper logbook of their lifestyle. Another way is for an individual to simply rely on remembering facts about their lifestyle and then relay these details to their physician on each visit.
The aforementioned methods of recording lifestyle information are inherently difficult, time consuming, and possibly inaccurate. Paper logbooks are not necessarily always carried by an individual and may not be accurately completed when required. Such paper logbooks are small and it is therefore difficult to enter detailed information requiring detailed descriptors of lifestyle events. Furthermore, an individual may often forget key facts about their lifestyle when questioned by a physician who has to manually review and interpret information from a hand-written notebook. There is no analysis provided by the paper logbook to distill or separate the component information. Also, there are no graphical reductions or summary of the information. Entry of data into a secondary data storage system, such as a database or other electronic system, requires a laborious transcription of information, including lifestyle data, into this secondary data storage. Difficulty of data recordation encourages retrospective entry of pertinent information that results in inaccurate and incomplete records.
There currently exist a number of portable electronic devices that can measure glucose levels in an individual and store the levels for recalling or uploading to another computer for analysis. One such device is the Accu-Check™ Complete™ System from Roche Diagnostics, which provides limited functionality for storing lifestyle data. However, the Accu-Check™ Complete™ System only permits a limited selection of lifestyle variables to be stored in a meter. There is a no intelligent feedback from values previously entered into the meter and the user interface is unintuitive for an infrequent user of the meter.
In an embodiment, a method of notifying a user of high or low trends in blood glucose values obtained with a diabetes management unit is provided. The unit includes a microprocessor coupled to a display, memory and user interface buttons. The method can be achieved by: performing with the microprocessor, a plurality of blood glucose measurements of the user; storing in the memory, the plurality of blood glucose measurements; determining whether a most recent blood glucose measurement at a given time during a day is below a first threshold or above a second threshold; evaluating with the microprocessor, whether at least one blood glucose measurement of the plurality of blood glucose measurements performed within a time frame of X hours about the given time of the most recent blood glucose measurement over a period of N days, is lower than the first threshold or higher than the second threshold; and upon achievement of the evaluating step, annunciating that in the same time frame of at least two days over the N number of days, the plurality of blood glucose measurements indicates a blood glucose trend lower than the low threshold or a blood glucose trend higher than a second threshold.
In yet a further embodiment, a diabetes management system is provided that includes a glucose test strip and a diabetes management unit. The diabetes management unit includes a housing, test strip port, plurality of user interface buttons and a microprocessor. The housing includes a test strip port configured to receive the glucose test strip. The microprocessor is coupled to the test strip port to provide data regarding an amount of glucose measured in a user's physiological fluid deposited on the test strip, the microprocessor further coupled to a memory, and user interface buttons. The microprocessor is programmed to: (a) perform a plurality of blood glucose measurements from the user; (b) store the plurality of blood glucose measurements; (c) determine whether a most recent blood glucose measurement at a given time during a day is below a first threshold or above a second threshold; (d) evaluate whether at least one blood glucose measurement of the plurality of blood glucose measurements performed within a time frame of X hours about the given time as the most recent blood glucose measurement over a period of N days, is lower than the first low threshold or higher than the second threshold; and (e) annunciate, upon achievement of the evaluation, that in the same time frame of at least two days over the N number of days, the plurality of blood glucose measurements indicates a trend lower than the low threshold or a trend higher than a second threshold.
These and other embodiments, features and advantages will become apparent to those skilled in the art when taken with reference to the following more detailed description of various exemplary embodiments of the invention in conjunction with the accompanying drawings that are first briefly described.
The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate presently preferred embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain features of the invention (wherein like numerals represent like elements).
The following detailed description should be read with reference to the drawings, in which like elements in different drawings are identically numbered. The drawings, which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations, alternatives and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.
As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein. In addition, as used herein, the terms “patient,” “host,” “user,” and “subject” refer to any human or animal subject and are not intended to limit the systems or methods to human use, although use of the subject invention in a human patient represents a preferred embodiment.
The electronic components of meter 10 can be disposed on a circuit board 34 that is within housing 11.
Operational amplifier circuit 35 can include two or more operational amplifiers configured to provide a portion of the potentiostat function and the current measurement function. The potentiostat function can refer to the application of a test voltage between at least two electrodes of a test strip. The current function can refer to the measurement of a test current resulting from the applied test voltage. The current measurement may be performed with a current-to-voltage converter. Microcontroller 38 can be in the form of a mixed signal microprocessor (MSP) such as, for example, the Texas Instrument MSP 430. The MSP 430 can be configured to also perform a portion of the potentiostat function and the current measurement function. In addition, the MSP 430 can also include volatile and non-volatile memory. In another embodiment, many of the electronic components can be integrated with the microcontroller in the form of an application specific integrated circuit (ASIC).
Strip port connector 22 can be configured to form an electrical connection to the test strip. Display connector 14a can be configured to attach to display 14. Display 14 can be in the form of a liquid crystal display for reporting measured glucose levels, and for facilitating entry of lifestyle related information. Display 14 can optionally include a backlight. Data port 13 can accept a suitable connector attached to a connecting lead, thereby allowing glucose meter 10 to be linked to an external device such as a personal computer. Data port 13 can be any port that allows for transmission of data such as, for example, a serial, USB, or a parallel port. Clock 42 can be configured to keep current time related to the geographic region in which the user is located and also for measuring time. The DMU can be configured to be electrically connected to a power supply such as, for example, a battery.
In one exemplary embodiment, test strip 24 can be in the form of an electrochemical glucose test strip. Test strip 24 can include one or more working electrodes and a counter electrode. Test strip 24 can also include a plurality of electrical contact pads, where each electrode can be in electrical communication with at least one electrical contact pad. Strip port connector 22 can be configured to electrically interface to the electrical contact pads and form electrical communication with the electrodes. Test strip 24 can include a reagent layer that is disposed over at least one electrode. The reagent layer can include an enzyme and a mediator. Exemplary enzymes suitable for use in the reagent layer include glucose oxidase, glucose dehydrogenase (with pyrroloquinoline quinone co-factor, “PQQ”), and glucose dehydrogenase (with flavin adenine dinucleotide co-factor, “FAD”). An exemplary mediator suitable for use in the reagent layer includes ferricyanide, which in this case is in the oxidized form. The reagent layer can be configured to physically transform glucose into an enzymatic by-product and in the process generate an amount of reduced mediator (e.g., ferrocyanide) that is proportional to the glucose concentration. The working electrode can then measure a concentration of the reduced mediator in the form of a current. In turn, glucose meter 10 can convert the current magnitude into a glucose concentration. Details of the preferred test strip are provided in U.S. Pat. Nos. 6,179,979; 6,193,873; 6,284,125; 6,413,410; 6,475,372; 6,716,577; 6,749,887; 6,863,801; 6,890,421; 7,045,046; 7,291,256; 7,498,132, all of which are incorporated by reference in their entireties herein.
Referring to
Where the user desires to access a main menu of the DMU, an actuation at 220 of one of the buttons of the DMU over a long duration (e.g., greater than 2 seconds) can be utilized to allow access to the main menu 230 in
Referring to
Where the user desires to calculate insulin bolus, the device can activate a calculation protocol 282 to provide a calculated insulin bolus. Three types of insulin boluses are described herein: (a) carbohydrate coverage, (b) glucose correction, or (c) a combination thereof. The insulin bolus amount for carbohydrate coverage may be an amount of insulin needed to account for carbohydrates about to be consumed at a meal. The insulin bolus amount for a glucose measurement correction may be an amount of insulin needed to account for a user's measured glucose value that is greater than a targeted euglycemic glucose value. The combination (e.g., carbohydrate value and measured glucose value) correction may be an amount of insulin needed to account for carbohydrates about to be consumed and the user's measured glucose value.
The glucose correction dose is an amount of insulin needed to account for a user's recently measured glucose value that is greater than the euglycemic zone. The carbohydrate coverage dose is an amount of insulin calculated based on the amount of carbohydrates to be consumed. The combination (e.g., carbohydrate value and measured glucose value) correction may be an amount of insulin needed to account for carbohydrates about to be consumed and the user's measured glucose value. Details of the insulin dosing calculation are provided in U.S. Provisional Patent Applications Ser. No. 61/246,630 filed 29 Sep. 2009, Ser. No. 61/297,573 filed 22 Jan. 2010, and Ser. No. 61/308,196, filed Feb. 25, 2010, all of the applications are hereby incorporated into this application.
Referring back to
Where a device setting 240 is desired, screen 243 is provided to allow for the selection of the following user's adjustable settings: time 244, date 246, language 248, and tool settings 250. A device information selection 252 and a previous screen selection 254 are also provided in screen 243. The tool setting selection 250 allows the user or a HCP to set up the DMU 10 for the user. In particular, once tool setting functionality 250 is selected, screen 302 is provided to allow for selection of various settings including set up for tagging or flagging field 304; set up for insulin calculation field 306; and set up for high/low trends field 308. To turn on the tagging or flagging function, screen 310 allows for the user to turn this feature on or off by scrolling a pointer over to field 304 in screen 302. To modify the insulin calculation, the user must scroll a pointer to field 306 for the process flow to switch over to screen 315. To modify the high/low trends alert, the user must scroll a pointer to field 308 for the process flow to switch over to a screen 312. Once high/low trends 308 is selected, screen 312 is provided to allow for selection of various settings including Trend Alerts 326 and My Trend Settings 328. To activate Trend Alerts 326, screen 314 allows for the user to turn this feature on or off. To adjust My Trend Settings 328, screen 316 allows for the user modify the thresholds. Modification to the thresholds can be made via screen 316 by selection of field 318 to modify a prestored low threshold at screen 322, or modify a prestored high setting by selection of field 320. As an exemplary embodiment, the modification to the high and low thresholds for trends functionality, reference is made to
In
On the other hand, where the logical operation at 313 returns a no, the unit is programmed to prevent enablement of the second threshold in screen 332 unless the tagging functionality is turned on. Should the user persist in selecting the blank second threshold, a message is displayed in screen 334 to the effect that the tagging functionality must be enabled in order for high trends to be detected. This is intended to help users understand the relationship between the Before Meal limit and tagging. In other words, if tagging of before meal measurements are not made, then there is little value in providing high trend messages. Additionally, even if tagging is enabled, the user is reminded by message 330 that tagging should be used consistently in order for the before meal high trend to be of value to the user.
In operation, a user would conduct a blood glucose measurement (200 in
In an alternative embodiment, at least three different screens (604a, 604b, 604c) in
On the other hand, with reference to
In an alternate embodiment of
In a scenario where the user is viewing the last blood glucose result, screen 724 is provided which allows the user the option of tagging this last blood glucose result at field 728. Screen 730 provides a menu of tagging fields. Once the user selects a “Before Meal” tag 732, screen 734 provides a general alert that a high trend has been detected at 736. Selection of field 736 causes screen 712 to display a more detailed indication that in 3 of N number of days there is a trend of high BG values at around the same time bracket in each of those 3 days.
Even though the user may select either a “Before Meal” tag or a “Fasting” tag, the microprocessor may be programmed to automatically infer that certain blood glucose measurements are measurements taken during a fasting period. In particular, with reference to the logic flow 750
In another scenario where the user is viewing menu screen 738, a general indication 740 can be provided to alert that a high (or fasting high) trend has been detected. Upon selection of field 740, screen 742 shows, for example, a table of the dates and times 743, 744, 745, and 746 that constitute the high trend.
In the preferred embodiments, the window of X hours includes about 6 hours and the N number of days may range from about 2 to about 21 days. In another preferred embodiment, the window of X hours include about 3 hours and the N number of days may range from about 2 to about 30 days, and most preferably from about 2 to about 5 days.
By virtue of the system and processes described herein, a method of notifying a user of high or low trends in blood glucose values obtained with a diabetes management unit is provided. The method may include the steps of: performing with the microprocessor, a plurality of blood glucose measurements; storing in the memory, the plurality of blood glucose measurements; determining whether a most recent blood glucose measurement is below a first threshold or above a second threshold; evaluating with the microprocessor, whether at least one blood glucose measurement of the plurality of blood glucose measurements performed within a time frame as the most recent blood glucose measurement over a period of N days, is lower than the first low threshold or higher than the second threshold; and upon achievement of the evaluating step, annunciating that in the same time frame of at least two days over the N number of days, the plurality of blood glucose measurements indicates a trend lower than the low threshold or a trend higher than a second threshold.
In a further alternative embodiment, shown here in
As an example of the logic 800, it will be assumed that a user conducted a series of measurements from Monday to Friday with a most recent BG result at 9 AM on Friday, as set forth in Table 1 below:
Referring to Table 1, the most recent BG has a logical true state for the logical queries 802 and 804 (i.e., exceeds the high threshold and flagged as fasting). At least one BG for each of the last four days has a logical true state for the logical queries 806 and 808. The logical query 810 must evaluate at least three BG's, which are the most recent BG (from queries 802 and 804) and the at least two BG's (from queries 806 and 808).
Based on the results collected in the previous 4 days, a warning message would be annunciated with the most recent BG on Friday at 9:00 AM. The 3 hour time bracket can include, in chronological order for time of day, 7:50 AM (Monday), 9:00 AM (Friday), and 10:49 AM (Tuesday), where the difference between the latest time and the earliest time is less than three hours (10:49 AM minus 7:50 AM=2 hours and 59 minutes). Thus, the Monday, Friday, and Tuesday BG's fall within the three hour time bracket. In addition to Monday, Friday, and Tuesday, the 3 hour time bracket can also include, in chronological order for time of day, 7:40 AM (Wednesday), 7:50 AM (Monday), and 9:00 AM (Friday), where the difference between the latest time and the earliest time is less than three hours (9:00 AM minus 7:40 AM=1 hour and 20 minutes).
Referring back to Table 1, there is no high trend alert for Wednesday. For Wednesday, 2 previous BG's and 1 most recent BG are evaluated in the logical query 810, which are 7:40 AM (Wednesday), 7:50 AM (Monday), and 10:49 AM (Tuesday), where the difference between the latest time and the earliest time is more than three hours (i.e., 10:49 AM minus 7:40 AM=3 hours and 9 minutes). Thus, the Wednesday, Monday, and Tuesday BG's do not fall within the three hour time bracket.
Referring back to Table 1, there is no high trend alert for Thursday. For Thursday, 2 previous BG's and 1 most recent BG are evaluated in the logical query 810. Note that there are three combinations of previous days that can be evaluated in the logical query 810, which are Monday/Tuesday; Monday/Wednesday; and Tuesday/Wednesday. Here, combining any one of the combinations of previous days with the most recent BG does not result in three BG's falling within the three hour time bracket.
Note that in the embodiment set forth in Table 1, only one glucose concentration per day was depicted that exceeds the high threshold and flagged as fasting. In other situations, there may be more than one glucose concentration per day that exceed the high threshold and are flagged as fasting. In such a case, the number of combinations of 3 BG's that need to be evaluated by the logic 800 will increase.
As a further demonstration of the applicability of logic routine 800, consider that the user further conducted a most recent BG measurement on the Saturday following the Friday (of Table 1), set forth here in Table 2.
In Table 2, the logic 800 would detect a high trend alert on Saturday (at 11:50 AM), which would be annunciated with the most recent BG. Note that there are six combinations of previous days that can be evaluated in the logical query 810, which are Monday/Tuesday; Monday/Wednesday; Monday/Thursday; Tuesday/Wednesday; Tuesday/Thursday; and Wednesday/Thursday. The 3 hour time bracket can include, in chronological order for time of day, 10:49 AM (Tuesday), 11:30 AM (Thursday), and 11:50 AM (Saturday), where the difference between the latest time and the earliest time is less than three hours (i.e., 11:50 AM minus 10:49 AM=1 hour and 1 minute). Thus, the Tuesday, Thursday, and Saturday BG's fall within the three hour time bracket. In summary based on Table 2, the user would be provided two messages: one on Friday and another message on Saturday. Alternatively, however, only one message may be generated on Saturday that reports the two high trends by prioritization of the trend data. Prioritization of the high trend or low trend reports can be based on the following: once a glucose value is used for a (high or low) trend, it will no longer be included in other (high/low) trends; if multiple trends are detected, the tightest clustering of results will be the one reported; or if there are multiple high and low BG measurements with an hour, only the first will be included in trend analysis (i.e., if there are either multiple high values with an hour or multiple low values within an hour, only the first will be included in trend analysis). Alternatively, the prioritization can be based on based on chronological closeness or based on the tightness of the clustering which can be determined by the closest 2 BG results in time to the most recent BG result, or the closest 3 BG results in time to the most recent BG result.
Although exemplary embodiments have been described in relation to a blood glucose meter, other diabetes management devices may also be utilized. For example, with reference to
Referring to
In yet a further alternative to the blood glucose meter 10, as shown in
Furthermore, the various methods described herein can be used to generate software codes using off-the-shelf software development tools such as, for example, Visual Studio 6.0, C or C++ (and its variants), Windows 2000 Server, and SQL Server 2000. The methods, however, may be transformed into other software languages depending on the requirements and the availability of new software languages for coding the methods. Additionally, the various methods described, once transformed into suitable software codes, may be embodied in any computer-readable storage medium that, when executed by a suitable microprocessor or computer, are operable to carry out the steps described in these methods along with any other necessary steps.
While the invention has been described in terms of particular variations and illustrative figures, those of ordinary skill in the art will recognize that the invention is not limited to the variations or figures described. In addition, where methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art will recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above. Therefore, to the extent there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is the intent that this patent will cover those variations as well.
This application claims the benefits of priority under 35 USC§119 and/or §120 from prior filed U.S. Provisional Application Ser. Nos. 61/308,217 filed on Feb. 25, 2010, and 61/322,697 filed on Apr. 9, 2010, which applications are incorporated by reference in their entirety into this application.
Number | Name | Date | Kind |
---|---|---|---|
4731726 | Allen | Mar 1988 | A |
5251126 | Kahn et al. | Oct 1993 | A |
5822715 | Worthington et al. | Oct 1998 | A |
6179979 | Hodges et al. | Jan 2001 | B1 |
6193873 | Ohara et al. | Feb 2001 | B1 |
6280409 | Stone et al. | Aug 2001 | B1 |
6284125 | Hodges et al. | Sep 2001 | B1 |
6309884 | Cooper et al. | Oct 2001 | B1 |
6379301 | Worthington et al. | Apr 2002 | B1 |
6413410 | Hodges et al. | Jul 2002 | B1 |
6425863 | Werner et al. | Jul 2002 | B1 |
6475372 | Ohara et al. | Nov 2002 | B1 |
6544212 | Galley et al. | Apr 2003 | B2 |
6558351 | Steil et al. | May 2003 | B1 |
6572542 | Houben et al. | Jun 2003 | B1 |
6633772 | Ford et al. | Oct 2003 | B2 |
6635167 | Batman et al. | Oct 2003 | B1 |
6656114 | Poulsen et al. | Dec 2003 | B1 |
6691043 | Ribeiro, Jr. et al. | Feb 2004 | B2 |
6716577 | Yu et al. | Apr 2004 | B1 |
6749887 | Dick et al. | Jun 2004 | B1 |
6862466 | Ackerman | Mar 2005 | B2 |
6863801 | Hodges et al. | Mar 2005 | B2 |
6890421 | Ohara et al. | May 2005 | B2 |
6941163 | Ford et al. | Sep 2005 | B2 |
7022072 | Fox et al. | Apr 2006 | B2 |
7024236 | Ford et al. | Apr 2006 | B2 |
7045046 | Chambers et al. | May 2006 | B2 |
7060059 | Keith et al. | Jun 2006 | B2 |
7179226 | Crothall et al. | Feb 2007 | B2 |
7204823 | Estes et al. | Apr 2007 | B2 |
7241265 | Cummings | Jul 2007 | B2 |
7267665 | Steil et al. | Sep 2007 | B2 |
7282029 | Poulsen et al. | Oct 2007 | B1 |
7291107 | Hellwig et al. | Nov 2007 | B2 |
7291256 | Teodorczyk et al. | Nov 2007 | B2 |
7354420 | Steil et al. | Apr 2008 | B2 |
7399277 | Saidara et al. | Jul 2008 | B2 |
7402153 | Steil et al. | Jul 2008 | B2 |
7404796 | Ginsberg | Jul 2008 | B2 |
7498132 | Yu et al. | Mar 2009 | B2 |
7509156 | Flanders | Mar 2009 | B2 |
7553281 | Hellwig et al. | Jun 2009 | B2 |
7651489 | Estes et al. | Jan 2010 | B2 |
8974387 | Shadforth | Mar 2015 | B2 |
20020019707 | Cohen et al. | Feb 2002 | A1 |
20020026111 | Ackerman | Feb 2002 | A1 |
20030108976 | Braig et al. | Jun 2003 | A1 |
20030175806 | Rule et al. | Sep 2003 | A1 |
20030208113 | Mault et al. | Nov 2003 | A1 |
20030211617 | Jones | Nov 2003 | A1 |
20030220814 | Gordon | Nov 2003 | A1 |
20040059201 | Ginsberg | Mar 2004 | A1 |
20050004439 | Shin et al. | Jan 2005 | A1 |
20050027182 | Siddiqui et al. | Feb 2005 | A1 |
20050038332 | Saidara et al. | Feb 2005 | A1 |
20050090726 | Ackerman | Apr 2005 | A1 |
20050096511 | Fox et al. | May 2005 | A1 |
20050096512 | Fox et al. | May 2005 | A1 |
20050113653 | Fox et al. | May 2005 | A1 |
20050143864 | Bloomquist | Jun 2005 | A1 |
20050176153 | O'Hara et al. | Aug 2005 | A1 |
20050182358 | Veit et al. | Aug 2005 | A1 |
20050214892 | Kovatchev et al. | Sep 2005 | A1 |
20060025663 | Talbot et al. | Feb 2006 | A1 |
20070010950 | Abensour et al. | Jan 2007 | A1 |
20070016127 | Staib et al. | Jan 2007 | A1 |
20070016449 | Cohen et al. | Jan 2007 | A1 |
20070060803 | Liljeryd et al. | Mar 2007 | A1 |
20070060813 | Chang | Mar 2007 | A1 |
20070083335 | Moerman et al. | Apr 2007 | A1 |
20070118589 | Brown | May 2007 | A1 |
20070173761 | Kanderiab, Jr. et al. | Jul 2007 | A1 |
20070208246 | Brauker et al. | Sep 2007 | A1 |
20070231914 | Deng et al. | Oct 2007 | A1 |
20070232880 | Siddiqui et al. | Oct 2007 | A1 |
20070276197 | Harmon | Nov 2007 | A1 |
20070287985 | Estes et al. | Dec 2007 | A1 |
20080045819 | Emoto et al. | Feb 2008 | A1 |
20080045825 | Melker et al. | Feb 2008 | A1 |
20080052057 | Brown | Feb 2008 | A1 |
20080097289 | Steil et al. | Apr 2008 | A1 |
20080119702 | Reggiardo et al. | May 2008 | A1 |
20080119710 | Reggiardo et al. | May 2008 | A1 |
20080125636 | Ward et al. | May 2008 | A1 |
20080139910 | Mastrototaro et al. | Jun 2008 | A1 |
20080154513 | Kovatchev et al. | Jun 2008 | A1 |
20080171967 | Bloomquist | Jul 2008 | A1 |
20080172027 | Bloomquist | Jul 2008 | A1 |
20080172028 | Bloomquist | Jul 2008 | A1 |
20080172029 | Bloomquist | Jul 2008 | A1 |
20080172031 | Bloomquist | Jul 2008 | A1 |
20080177154 | Hansen et al. | Jul 2008 | A1 |
20080183060 | Steil et al. | Jul 2008 | A1 |
20080187943 | Buse et al. | Aug 2008 | A1 |
20080188796 | Steil et al. | Aug 2008 | A1 |
20080199465 | Lake et al. | Aug 2008 | A1 |
20080206799 | Blomquist | Aug 2008 | A1 |
20080234943 | Ray et al. | Sep 2008 | A1 |
20080234992 | Ray et al. | Sep 2008 | A1 |
20080235053 | Ray | Sep 2008 | A1 |
20080255438 | Saidara et al. | Oct 2008 | A1 |
20080262088 | Hauck et al. | Oct 2008 | A1 |
20080268485 | Guarino et al. | Oct 2008 | A1 |
20080269585 | Ginsberg | Oct 2008 | A1 |
20080294024 | Cosentino et al. | Nov 2008 | A1 |
20080312512 | Brukalo et al. | Dec 2008 | A1 |
20080312518 | Jina et al. | Dec 2008 | A1 |
20090006129 | Thukral et al. | Jan 2009 | A1 |
20090018495 | Panduro | Jan 2009 | A1 |
20090018779 | Cohen et al. | Jan 2009 | A1 |
20090030733 | Cohen et al. | Jan 2009 | A1 |
20090098587 | Hetzel et al. | Apr 2009 | A1 |
20090099506 | Estes et al. | Apr 2009 | A1 |
20090099509 | Estes et al. | Apr 2009 | A1 |
20090105570 | Sloan et al. | Apr 2009 | A1 |
20090112069 | Kanamori et al. | Apr 2009 | A1 |
20090112626 | Talbot et al. | Apr 2009 | A1 |
20090137455 | Steiner et al. | May 2009 | A1 |
20090149717 | Brauer et al. | Jun 2009 | A1 |
20090150186 | Cohen et al. | Jun 2009 | A1 |
20090156923 | Power et al. | Jun 2009 | A1 |
20090156924 | Shariati et al. | Jun 2009 | A1 |
20090177147 | Blomquist et al. | Jul 2009 | A1 |
20090184004 | Chatiler et al. | Jul 2009 | A1 |
20090237262 | Smith et al. | Sep 2009 | A1 |
20090240127 | Ray | Sep 2009 | A1 |
20090247982 | Krulevitch et al. | Oct 2009 | A1 |
20090292190 | Miyashita | Nov 2009 | A1 |
20100016700 | Sieh et al. | Jan 2010 | A1 |
20100041084 | Stephens et al. | Feb 2010 | A1 |
20100041960 | Yuan et al. | Feb 2010 | A1 |
20100174228 | Buckingham et al. | Jul 2010 | A1 |
20100331654 | Jerdonek | Dec 2010 | A1 |
20110050428 | Istoc | Mar 2011 | A1 |
20110205064 | Strachan | Aug 2011 | A1 |
20130318439 | Landis | Nov 2013 | A1 |
Number | Date | Country |
---|---|---|
0483595 | Dec 2001 | EP |
1338295 | Aug 2003 | EP |
1568310 | Aug 2005 | EP |
1677226 | Jul 2006 | EP |
1770396 | Apr 2007 | EP |
1840219 | Oct 2007 | EP |
2455875 | May 2012 | EP |
2007317196 | Dec 2007 | JP |
2008501426 | Jan 2008 | JP |
2008508029 | Mar 2008 | JP |
2009037588 | Feb 2009 | JP |
WO 9837805 | Sep 1998 | WO |
WO 0200112 | Jan 2002 | WO |
WO 03030731 | Apr 2003 | WO |
WO 03045233 | Jun 2003 | WO |
WO 2004015539 | Feb 2004 | WO |
WO 2004023972 | Mar 2004 | WO |
WO 2005093629 | Oct 2005 | WO |
WO 2006066038 | Jun 2006 | WO |
WO 2006066583 | Jun 2006 | WO |
WO 2006133348 | Dec 2006 | WO |
WO 2007005170 | Jan 2007 | WO |
WO 2007019289 | Feb 2007 | WO |
WO 2007019384 | Feb 2007 | WO |
WO 2007028271 | Mar 2007 | WO |
WO 2007101260 | Sep 2007 | WO |
WO 2007149533 | Dec 2007 | WO |
WO 2008071218 | Jun 2008 | WO |
WO 2008071444 | Jun 2008 | WO |
WO 2008073609 | Jun 2008 | WO |
WO 2008094249 | Aug 2008 | WO |
WO 2009005952 | Jan 2009 | WO |
WO 2009005960 | Jan 2009 | WO |
WO 2009016050 | Feb 2009 | WO |
WO 2009137661 | Nov 2009 | WO |
2011002791 | Jan 2011 | WO |
Entry |
---|
International Search Report, PCT Application No. PCT/US2010/040425, Dated Dec. 23, 2010, 7 pages, European Patent Office, Rijswijk, Netherlands. |
Partial International Search Report, Annex to Form PCT/ISA/206, PCT Application No. PCT/US2010/040309, Dated Nov. 29, 2010, 2 pages, European Patent Office, Rijswijk, Netherlands. |
International Search Report, PCT Application No. PCT/GB2010/001683, Dated Dec. 22, 2010, 4 pages, European Patent Office, Rijswijk, Netherlands. |
Nathan, D.M., Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy, Diabetes Care, vol. 29 No. 8, 1963-1972, Aug. 2006. |
International PCT Patent Application No. PCT/US2010/040434, International Search Report, dated Oct. 20, 2010, 3 pgs, European Patent Office, Rijswijk. |
International Search Report, PCT Application No. PCT/US2010/040383, dated Nov. 4, 2010, 3 pages, European Patent Office, Rijswijk. |
William H. et al. Numerical Recipes in C: The Art of Scientific Computing. Cambridge: Cambridge University Press, 1992. ISBN 0-521-43108-5, pp. 226-230. |
“Accu-Chek Complete Owner's Booklet”, Roche Diagnostics, 2004, XP002636883, Retrieved from internet: URL:https://www.accu-chek.com/us/customer-care/downloads.html [retrieved May 12, 2011], p. 8, pp. 33-40, pp. 46 and 86. |
International Search Report, PCT Application No. PCT/US2010/040443, dated May 17, 2011, 3 pages, European Patent Office, Rijswijk, NL. |
European Application No. 10730658.1, European Office Action dated Aug. 20, 2013, 4 pages. |
Patent Examination Report issued in related Australian Patent Application No. 2010346623, dated May 30, 2014, 3 pages. |
European Search Report issued in related European Patent Application No. EP 13 15 1121, dated Apr. 10, 2013, 6 pages. |
European Search Report issued in related European Patent Application No. Ep 13 15 1120, dated Apr. 10, 2013, 6 pages. |
International Preliminary Report on Patentability issued in related International Application No. PCT/US2010/040434, May 31, 2012, 10 pages. |
Notice of Reasons for Rejection issued in related Japanese Patent Application No. 2012-554979, dated Apr. 8, 2014, 4 pages. |
Written Opinion issued in related International Application No. PCT/US2010/040434, Mar. 12, 2012, 6 pages. |
Patent Examination Report issued in related Australian Application No. 2010346623, dated Jun. 4, 2015, 3 pages. |
Notice of Preliminary Rejection issued in related Korean Patent Application No. 10-2012-7024554, mailed May 3, 2016, 15 pages. |
Office Action issued in related Chinese Patent Application No. 201080064763.2, mailed Dec. 3, 2014, 17 pages. (Note: English translation will be provided upon request). |
Notification on the Results of Patentability Check issued in related Russian Patent Application No. 2012140731, dated Jul. 7, 2014, 14 pages. |
Number | Date | Country | |
---|---|---|---|
20110205064 A1 | Aug 2011 | US |
Number | Date | Country | |
---|---|---|---|
61308217 | Feb 2010 | US | |
61322697 | Apr 2010 | US |